Synthetic DNA & Novel Env Vaccine for HIV
Synthetic DNA & Novel Env Vaccine for HIV
批准号:
9024416
负责人:
DAVID B. WEINER
金额:
$342.45万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-03-01 至 2020-02-29
关键词:
ALVACAdjuvantAntibodiesAntibody ResponseAntigensAutomobile DrivingCXCL13 geneClinicClinicalClinical TrialsCollaborationsCollectionConsensusCore ProteinDNADNA VaccinesDevelopmentDevicesElectroporationEquilibriumGenesGeneticGoalsHIVHIV Envelope Protein gp120HIV Vaccine Trials NetworkHIV vaccineImmuneImmune responseImmunityImmunizationInterleukin-12LifeLightModalityOutcomePlasmidsProductionProductivityProteinsRecombinant ProteinsResearch PersonnelSchemeSeasonsSerologicalSkinSurfaceT cell responseT-LymphocyteTechnologyTestingVaccine AdjuvantVaccinesViral VectorWorkchemokinecytokinedesignimprovedinnovationinterestmembernext generationnovelpre-clinicalprogramspublic health relevanceresponsesimian human immunodeficiency virussuccesssynthetic constructvaccine developmentvaccine responsevaccine trialvectorvector vaccine
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The goal of this program to produce an enhanced E/P delivered gene adjuvanted DNA vaccine (E-DNA) and combine this with a highly novel polyvalent A, B, C, A/E recombinant protein boost (PPB) as a vaccine platform. The EP focus of this application is to utilize novel surface delivery. By this combination we hypothesize that we will generate an improved spectrum of T and B anti HIV immune responses compared to current HIV vaccine modalities. This project builds on a major innovations and accomplishments by the members of this team that have led to this proposal. The team has worked together productively for multiple years. Furthermore they have an outstanding track record of productivity working with the HVTN. The inclusion of CHAVI investigators as part of the preclinical development immune analysis is a major strength of the program. There are 3 highly interrelated, translational focused, exceptionally novel projects which build on a strong track record of accomplishment together that comprise this program. They are supported by a highly respected and critical protein core as well as seasoned administrative core.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
2023 International Society for Vaccines (ISV) Annual Congress, October 22-25, Lausanne, Switzerland
-
批准号:10754840
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2023
-
负责人:DAVID B. WEINER
-
依托单位:
Administrative Core
-
批准号:10589586
-
项目类别:
-
资助金额:$72.69万
-
财政年份:2022
-
负责人:DAVID B. WEINER
-
依托单位:
Administrative Core
-
批准号:10328139
-
项目类别:
-
资助金额:$27.52万
-
财政年份:2022
-
负责人:DAVID B. WEINER
-
依托单位:
Rapid, single-dose coronavirus vaccines via DNA-launched nanoparticles and genetic adjuvants for durable anti-coronavirus immunity
-
批准号:10328141
-
项目类别:
-
资助金额:$110.71万
-
财政年份:2022
-
负责人:DAVID B. WEINER
-
依托单位:
Synthetic DNA-launched and adjuvanted Env immunogens for HIV
-
批准号:10589585
-
项目类别:
-
资助金额:$449.79万
-
财政年份:2022
-
负责人:DAVID B. WEINER
-
依托单位:
Design and optimization of DL-NLTs and molecular adjuvants to increase potency and promote NAb formation in vivo
-
批准号:10589587
-
项目类别:
-
资助金额:$142.76万
-
财政年份:2022
-
负责人:DAVID B. WEINER
-
依托单位:
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
-
批准号:10459450
-
项目类别:
-
资助金额:$97.92万
-
财政年份:2019
-
负责人:DAVID B. WEINER
-
依托单位:
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
-
批准号:10004562
-
项目类别:
-
资助金额:$115.33万
-
财政年份:2019
-
负责人:DAVID B. WEINER
-
依托单位:
Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection
-
批准号:10228693
-
项目类别:
-
资助金额:$95.06万
-
财政年份:2019
-
负责人:DAVID B. WEINER
-
依托单位:
Administration
-
批准号:9261462
-
项目类别:
-
资助金额:$21.39万
-
财政年份:2017
-
负责人:DAVID B. WEINER
-
依托单位:
Multivalent DNA vaccine-mediated protection against Tuberculosis
-
批准号:10297846
-
项目类别:
-
资助金额:$86.53万
-
财政年份:2017
-
负责人:DAVID B. WEINER
-
依托单位:
Multivalent DNA vaccine-mediated protection against Tuberculosis
-
批准号:10054982
-
项目类别:
-
资助金额:$90.84万
-
财政年份:2017
-
负责人:DAVID B. WEINER
-
依托单位:
Synthetic DNA & Novel Env Vaccine for HIV
-
批准号:9261455
-
项目类别:
-
资助金额:$333.75万
-
财政年份:2015
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:8721834
-
项目类别:
-
资助金额:$36.08万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:8317646
-
项目类别:
-
资助金额:$111.31万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:8525084
-
项目类别:
-
资助金额:$54.8万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:8143485
-
项目类别:
-
资助金额:$42.85万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:9352656
-
项目类别:
-
资助金额:$10.75万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Development of a Universal Influenza Seasonal Vaccine
-
批准号:8017652
-
项目类别:
-
资助金额:$47.65万
-
财政年份:2010
-
负责人:DAVID B. WEINER
-
依托单位:
Training in Vaccine & Immune Therapeutics
-
批准号:7503022
-
项目类别:
-
资助金额:$19.41万
-
财政年份:2008
-
负责人:DAVID B. WEINER
-
依托单位:
海外基金